Navigation Links
ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
Date:1/7/2008

MENLO PARK, Calif., Jan. 7 /PRNewswire/ -- ForSight Labs, LLC announced today the formation and funding of its third company, ForSight VISION3, Inc. with a Series A financing of $6 million, supported by three of the leading venture capital firms in the medical technology arena: Morgenthaler Ventures, Split Rock Partners and Versant Ventures.

"We are excited to have closed a significant round of funding to develop our next innovative ophthalmic technology," said K. Angela Macfarlane, President and CEO of ForSight VISION3. "The ForSight team is already assessing dramatic new opportunities."

The existing ForSight VISION companies, Transcend Medical, and ForSight Newco II (now a wholly owned subsidiary of QLT, Inc.) have each developed high impact products for major ophthalmic markets.

"Ophthalmology continues to have a considerable need for new technologies to address vision loss in all market segments," said Eugene de Juan, Jr. MD, Founder and Vice Chairman of ForSight Labs. "ForSight VISION3 is well positioned to carefully select and develop successful product solutions." Each of the venture partnerships will take a seat on the ForSight VISION3 Board of Directors.

About ForSight Labs, LLC

ForSight Labs is a community of ophthalmic innovation focused on improving the sight, care, and quality of life of visually impaired patients by creating high-impact eye care companies (http://www.forsightlabs.com). ForSight Labs, LLC was established in 2005 by renowned ophthalmologist and retinal surgeon Eugene de Juan, Jr. MD in collaboration with The Foundry (http://www.thefoundry.com). In late 2006, ForSight Labs launched its first company, Transcend Medical, Inc. In October 2007, its second spin out company ForSight Newco II, Inc., developing a proprietary ocular punctal plug drug delivery system, was acquired by QLT Inc. (Nasdaq: QLTI; TSX: QLT). ForSight Labs is backed by investors Morgenthaler Ventures (http://www.morgenthaler.com), Split Rock Partners (http://www.splitrock.com), and Versant Ventures (http://www.versantventures.com).

About Morgenthaler Ventures

Morgenthaler Ventures is a leading, national venture capital team with offices in Menlo Park, CA; Boston, MA; Princeton, NJ, Boulder, CO; and Cleveland, OH. It concentrates its investments in life sciences and information technology.

Morgenthaler's Life Science Team focuses on medical devices and therapeutic pharmaceuticals. Recent investments include Avidia, Morphotek, Threshold Pharmaceuticals, Replidyne, Orexigen, Thermage, Emphasys, Satiety, Cierra, Ardian, Cabochon Aesthetics, Transcend and Xtent. The firm has approximately $2.5 billion under management and has funded more than 250 companies since 1968. For more information on Morgenthaler portfolio companies and the firm, please visit: http://www.morgenthaler.com/ventures.

About Split Rock Partners

Split Rock Partners, with offices in Menlo Park and Minneapolis, invests in emerging opportunities in healthcare and internet services primarily on the West Coast and the Upper Midwest. Split Rock Partners was formed in June, 2004 by the healthcare and software investment teams of St. Paul Venture Capital. In April, 2005, Split Rock announced the closing of a new $275 million venture fund. Split Rock Partners' portfolio of healthcare investments has included such industry leading companies as SpineTech, The Foundry, Dexcom, Emphasys Medical, Xtent, Atritech, Prometheus Labs, and many others. Additional information about the firm can be found at http://www.splitrock.com.

About Versant Ventures

Founded in 1999, Versant Ventures is a leading healthcare venture capital firm that currently manages over $1 billion in committed capital. Since its formation, Versant has invested in more than 75 companies in the Medical Device, Biotech, Healthcare Services and Healthcare Information Technology sectors. The Versant team of twelve investment professionals located in Menlo Park and Newport Beach bring together more than 175 years of combined experience and success as venture capitalists and entrepreneurs. Versant invests in early-stage healthcare companies promising to be significant, long-term market leaders. For additional information, please visit http://www.versantventures.com.


'/>"/>
SOURCE ForSight Labs, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QLT Completes Acquisition of ForSight Newco II, Inc.
2. ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc.
3. QLT acquires leading edge ocular drug delivery system from ForSight Labs
4. Barc Announces New Travel Size for Its Razor Bump Relief Product
5. Immucor Announces Update to Second Quarter Conference Call Number
6. New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. amfAR announces inaugural Mathilde Krim Fellowship Awards for AIDS research
11. Torchmark Corporation Announces Change in Domicile State of Insurance Subsidiaries to Nebraska
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)...  Mirabilis Medical, a Seattle ... surgery, announced today CE Mark authorization for marketing ... fibroids throughout the European Union.  The company simultaneously ... US Food and Drug Administration to begin a ... United States.  The Mirabilis System combines high-speed therapeutic ...
Breaking Medicine Technology: